According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
Several other equities analysts have also commented on the stock. BidaskClub lowered shares of Vertex Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday. JPMorgan Chase & Co. lowered shares of Sogou from a neutral rating to an underweight rating and dropped their price target for the stock from $5.50 to $4.12 in a research report on Thursday, June 27th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of Hold and an average price target of $20.75.
GRIFOLS S A/S (NASDAQ:GRFS) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.25. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. GRIFOLS S A/S had a net margin of 12.35% and a return on equity of 15.49%. Equities analysts expect that GRIFOLS S A/S will post 1.27 earnings per share for the current year.
The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, June 18th. Investors of record on Monday, June 10th were given a dividend of $0.14 per share. The ex-dividend date of this dividend was Friday, June 7th. GRIFOLS S A/S’s dividend payout ratio (DPR) is 22.22%.
A number of hedge funds have recently modified their holdings of GRFS. Raymond James & Associates increased its position in GRIFOLS S A/S by 75.9% during the fourth quarter. Raymond James & Associates now owns 20,090 shares of the biotechnology company’s stock worth $369,000 after purchasing an additional 8,670 shares during the last quarter. Advisor Group Inc. increased its position in GRIFOLS S A/S by 18.7% during the fourth quarter. Advisor Group Inc. now owns 25,065 shares of the biotechnology company’s stock worth $460,000 after purchasing an additional 3,941 shares during the last quarter. Northern Trust Corp increased its position in GRIFOLS S A/S by 4.3% during the fourth quarter. Northern Trust Corp now owns 544,975 shares of the biotechnology company’s stock worth $10,006,000 after purchasing an additional 22,602 shares during the last quarter. Two Sigma Investments LP increased its position in GRIFOLS S A/S by 22.2% during the fourth quarter. Two Sigma Investments LP now owns 819,034 shares of the biotechnology company’s stock worth $15,037,000 after purchasing an additional 148,900 shares during the last quarter. Finally, Two Sigma Advisers LP increased its position in GRIFOLS S A/S by 502.7% during the fourth quarter. Two Sigma Advisers LP now owns 134,400 shares of the biotechnology company’s stock worth $2,468,000 after purchasing an additional 112,100 shares during the last quarter. 19.01% of the stock is owned by hedge funds and other institutional investors.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
See Also: Trade Deficit
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.